← Back to Home

Tracking Trace DNA After Cancer Surgery: Abbott Launches Whole-Genome Oncodetect Blood Test

The updated test tracks more of each patient’s tumor-specific variants. A colorectal cancer study showed a 30-percentage-point increase in sensitivity for identifying recurrence within two years from a single postoperative blood draw. Whether detecting cancer signals earlier can translate into better treatment outcomes remains to be verified.

By SURL BioNews

After surgery removes a visible tumor, whether microscopic disease remains in the body is often one of the hardest questions to answer following cancer treatment. On October 26, Abbott announced the launch of an updated Oncodetect molecular residual disease (MRD) blood test, combining whole-genome sequencing with tumor DNA enrichment technology in the hope of providing clearer clues about recurrence risk when cancer signals in the blood are extremely scarce.

The test first analyzes a patient’s tumor tissue to identify individual DNA variants, then searches the blood for the same signals, known as circulating tumor DNA (ctDNA). The updated version expands its search from the whole exome to the whole genome, increasing the number of patient-specific variants it can track from up to 200 to 5,000 and providing more opportunities to capture trace residual signals.

One key component is MAESTRO technology, developed by the Broad Institute. Researchers design probes based on tumor variants to preferentially capture DNA fragments carrying mutations, then reduce the uncaptured normal DNA in the sample. Broad explains that this approach can reduce the amount of sequencing subsequently required. The institute licensed the technology to Exact Sciences in 2023 and collaborated to advance its clinical application in Oncodetect.

Abbott said that with higher sample input, the updated test’s limit of detection can be below one part per million. In an interview with MedTech Dive, Rick Baehner, the company’s chief medical officer for precision oncology, described the previous version’s limit of detection as 15 to 50 parts per million. However, the lowest concentration of DNA that an analytical test can detect and the proportion of patients with subsequent recurrence that it can identify clinically are different measures and cannot be directly equated.

Clinical evidence comes from the Beta-CORRECT study, which Abbott presented at the European Society for Medical Oncology (ESMO) annual meeting. It analyzed postoperative samples from 279 patients with colorectal cancer, predominantly those with stage II or III disease. According to the company’s report, using a single blood draw approximately one month after surgery, the updated test had a sensitivity of 72.2% for identifying recurrence within two years, compared with 42.2% for the previous version, an increase of 30 percentage points. Among 157 patients tested with both versions, the updated test identified all 29 ctDNA-positive patients detected by the previous version, plus 15 additional positive patients.

These signals were also clearly associated with prognosis: the two-year disease-free survival rate was 36.2% among patients who were ctDNA-positive after surgery, compared with 92.3% among those who were negative. This supports the test’s potential to distinguish recurrence risk, but a negative result still cannot rule out recurrence. The risk association shown in the study also does not yet establish that adjusting treatment based on the updated test can prolong patients’ survival.

According to MedTech Dive’s account of Baehner’s comments, more than 20 studies are currently evaluating the updated test across different solid tumors. The current colorectal cancer results come from a conference presentation and company-released data; further follow-up will help clarify its clinical uses. Oncodetect is performed by a laboratory that meets U.S. CLIA requirements. It has not received approval or clearance from the U.S. Food and Drug Administration (FDA), and its performance cannot be directly extrapolated to cancer types not included in clinical validation.

References

  1. Abbott
  2. Broad Institute
  3. Abbott